MyBiotics Pharma

Clinically Effective Microbiome and Probiotic Products

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in July 2014 by Didi Daboush, MyBiotics Pharma operates with 11–50 employees. The company has raised $11.27 million across five funding rounds, with Maruho Israel Innovation Fund participating in one. In January 2022, MyBiotics announced the successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, marking a significant step in developing new restoration therapies.

Business overview

MyBiotics Pharma is a microbiome company dedicated to enhancing human health through advanced probiotic solutions. The company has developed a proprietary technological platform for creating microbiome-related drugs and supplements, utilizing innovative formulation, delivery, and culturing methods to improve viability, resistance, and clinical outcomes. MyBiotics' core technologies include MyCrobe, SuperDonor, and Super Donor Select, all supported by its MyLiveIn computational and AI platform. The company is currently in the clinical stage with three products, including MBX-SD-201 and MBX-SD-202, which leverage its SuperDonor technology for microbiome restoration. MyBiotics serves the Health Tech & Life Sciences sector, focusing on areas such as C. diff, oncology, dermatology, and women's health through collaborations with pharmaceutical and clinical partners.

Strategic signal

In January 2022, MyBiotics Pharma announced the successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment. This milestone is crucial as it validates the safety and initial efficacy of their innovative microbiome culturing technology, paving the way for advanced restoration therapies. For investors, this signals significant progress in MyBiotics' clinical development pipeline and strengthens its position as a key player in the microbiome therapeutics market.

Company Intelligence Q&A

What was a significant clinical development for MyBiotics Pharma?
In January 2022, MyBiotics Pharma announced the successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, which is designed to drive innovative restoration therapies using microbiome culturing technology.
What was MyBiotics Pharma's collaboration with Galmed?
In November 2020, MyBiotics and Galmed collaborated to develop a bespoke microbiome signature for Aramchol, focusing on the interplay between the microbiome and specific therapeutic compounds.
Which investor participated in MyBiotics Pharma's February 2021 funding round?
In February 2021, MyBiotics Pharma received an investment from Maruho Israel Innovation Fund.
What grant did MyBiotics Pharma receive in October 2020?
In October 2020, MyBiotics Pharma was awarded a $2.3 million grant from EU Horizon 2020, as reported by Geektime.
What was the nature of MyBiotics Pharma's collaboration with Ferring and Rebiotix?
In February 2021, Ferring, Rebiotix, and MyBiotics collaborated to develop live microbiome-based therapeutics specifically for reproductive medicine and maternal health.

External links